O Brien Greene & Co. Inc Sells 302 Shares of Bristol-Myers Squibb (NYSE:BMY)

O Brien Greene & Co. Inc cut its stake in shares of Bristol-Myers Squibb (NYSE:BMY) by 4.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 6,108 shares of the biopharmaceutical company’s stock after selling 302 shares during the quarter. O Brien Greene & Co. Inc’s holdings in Bristol-Myers Squibb were worth $313,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. OFI Invest Asset Management bought a new stake in Bristol-Myers Squibb during the 3rd quarter valued at $25,000. Milestone Investment Advisors LLC purchased a new stake in shares of Bristol-Myers Squibb in the 3rd quarter worth approximately $27,000. Blue Bell Private Wealth Management LLC boosted its stake in shares of Bristol-Myers Squibb by 61.5% during the third quarter. Blue Bell Private Wealth Management LLC now owns 525 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 200 shares in the last quarter. Legacy Financial Group LLC purchased a new position in Bristol-Myers Squibb during the third quarter valued at approximately $39,000. Finally, Turtle Creek Wealth Advisors LLC bought a new position in Bristol-Myers Squibb in the fourth quarter worth approximately $40,000. Institutional investors own 76.41% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on BMY. William Blair reaffirmed a “market perform” rating on shares of Bristol-Myers Squibb in a research report on Monday, April 1st. Barclays cut their price objective on shares of Bristol-Myers Squibb from $51.00 to $43.00 and set an “equal weight” rating on the stock in a research report on Friday. Societe Generale cut shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research report on Monday, March 11th. Bank of America lowered shares of Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and cut their price target for the stock from $68.00 to $60.00 in a report on Wednesday, January 3rd. Finally, StockNews.com lowered Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a research report on Monday, April 15th. One equities research analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $60.00.

Bristol-Myers Squibb Stock Up 0.4 %

Bristol-Myers Squibb stock opened at $44.86 on Friday. The company has a quick ratio of 1.31, a current ratio of 1.43 and a debt-to-equity ratio of 1.24. The business’s 50-day moving average price is $51.03 and its 200 day moving average price is $51.18. Bristol-Myers Squibb has a 52 week low of $44.34 and a 52 week high of $69.10. The firm has a market cap of $90.92 billion, a price-to-earnings ratio of -14.47, a price-to-earnings-growth ratio of 16.25 and a beta of 0.39.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($4.40) EPS for the quarter, beating the consensus estimate of ($4.53) by $0.13. The company had revenue of $11.87 billion for the quarter, compared to analyst estimates of $11.45 billion. Bristol-Myers Squibb had a positive return on equity of 50.04% and a negative net margin of 13.50%. Bristol-Myers Squibb’s quarterly revenue was up 4.7% compared to the same quarter last year. During the same period last year, the company earned $2.05 earnings per share. As a group, sell-side analysts anticipate that Bristol-Myers Squibb will post 0.55 earnings per share for the current year.

Bristol-Myers Squibb Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 1st. Investors of record on Friday, April 5th will be issued a $0.60 dividend. This represents a $2.40 annualized dividend and a yield of 5.35%. The ex-dividend date of this dividend is Thursday, April 4th. Bristol-Myers Squibb’s payout ratio is -77.42%.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.